Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
7
×
boston top stories
life sciences
national blog main
boston
clinical trials
national top stories
san francisco blog main
new york blog main
san diego blog main
depression
dyne therapeutics
indiana blog main
indiana top stories
myotonic dystrophy type 1
new york top stories
rare disease drugs
rare diseases
san diego top stories
san francisco top stories
third rock ventures
abbvie
allergan
ally bridge group
alzheimer's disease
antidepressant
antisense oligonucleotide
assurex health
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
benzodiazepines
big data analytics
biogen
biotech ipos
blackrock
blackstone group
What
genetic
7
×
medicines
drug
ipo
new
biotech
cancer
company
diseases
dyne
experimental
million
muscle
raised
rare
research
therapeutics
treatment
abbvie
address
ago
aims
alliance
analysis
approval
approves
backed
bio
biotechs
blueprint
bring
brings
carries
cause
centers
ceo
certain
considering
cut
data
Language
unset
Current search:
genetic
×
biotech
×
" boston blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?